Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    Sirolimus

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    SIROLIMIUS

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palvella Presents QTORIN Data for Rare Vascular Malformations
    Palvella Presents QTORIN Data for Rare Vascular Malformations

    20 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/20/3298897/0/en/Palvella-Therapeutics-Presents-New-SELVA-and-TOIVA-Data-at-the-2026-International-Society-for-the-Study-of-Vascular-Anomalies-World-Congress-Supporting-QTORIN-Rapamycin-as-a-Potent.html

    GLOBENEWSWIRE
    20 May 2026
    Share Share
    Reflow Medical Reports 6-Month DEEPER CORONARY Study Results
    Reflow Medical Reports 6-Month DEEPER CORONARY Study Results

    20 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260520334491/en/Reflow-Medical-Reports-Six-Month-Results-from-DEEPER-CORONARY-Study-of-Spur-Elute-Stent

    BUSINESSWIRE
    20 May 2026
    Share Share
    Palvella Initiates Phase2 For QTORIN Rapamycin for Angiokeratomas
    Palvella Initiates Phase2 For QTORIN Rapamycin for Angiokeratomas

    04 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/04/3286595/0/en/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-lotu-trial-of-fast-track-designated-qtorin-rapamycin-for-clinically-significant-angiokeratomas.html

    GLOBENEWSWIRE
    04 May 2026
    Share Share
    Concept Medical Reveals Positive 3-Year Results For Sirolimus
    Concept Medical Reveals Positive 3-Year Results For Sirolimus

    28 Apr 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/medical-device/concept-medical-unveils-promising-3-year-data-for-sirolimus-balloon-therapy-19947

    INDPHARMAPOST
    28 Apr 2026
    Share Share
    Quoin Pharma Provides QRX009 Clinical and Regulatory Update
    Quoin Pharma Provides QRX009 Clinical and Regulatory Update

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282671/0/en/quoin-pharmaceuticals-provides-clinical-and-regulatory-update-for-qrx009-topical-rapamycin-development-programs.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Concept Medical unveils landmark SirPAD trial at ACC 2026
    Concept Medical unveils landmark SirPAD trial at ACC 2026

    03 Apr 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/medical-device/concept-medical-unveils-landmark-sirpad-trial-at-acc-2026-advancing-pad-treatment-19529

    INDPHARMAPOST
    03 Apr 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.